Results 101 to 110 of about 7,686 (201)

Effects of Alirocumab and Evolocumab on Cardiovascular Mortality and LDL-C: Stratified According to the Baseline LDL-C Levels

Reviews in Cardiovascular Medicine
Background: A meta-analysis was conducted to determine whether the cardiovascular mortality and lipid-lowering effects of alirocumab and evolocumab are influenced by various baseline low-density lipoprotein cholesterol (LDL-C) levels.
Hui Ma, Wenfang Ma, Yang Liu, Lixing Chen, Peng Ding   +4 more
doaj   +1 more source

HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment? [PDF]

, 2016
Morozzi, Claudia, Stefanutti, Claudia
core   +1 more source

PCSK9 antagonists and inflammation [PDF]

, 2018
Corsini, Alberto, Ferri, Nicola, Ruscica, Massimiliano, Sirtori, Cesare R.   +3 more
core   +1 more source

Effects of residual inflammatory and cholesterol risks on cardiovascular events with evolocumab in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Lipids in Health and Disease
Background Evolocumab has shown significant reductions in low-density lipoprotein cholesterol (LDL-C) levels and incident cardiovascular events among acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Nonetheless,
Yahao Zhang, Kairu Li, Xiangwei Bo, Yanghui Zhang, Tingting Xiao, Huan Liu, Orion I. R. Chiara Villamil, Kui Chen, Jiandong Ding   +8 more
doaj   +1 more source

Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis

Medicina
Background and Objectives: The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab are recently developed promising drugs used for treatment of familial hypercholesterolemia (FH).
Guoguang Xiao, Shan Gao, Yongmei Xie, Zhiling Wang, Min Shu   +4 more
doaj   +1 more source

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects

Clinical Pharmacology: Advances and Applications, 2019
Chao Liu,1 Hong Lu,2 Fei Yuan,1 Wei-Li Chen,1 Hong-Rong Xu,1 Hui Li,1 Cheng-Pang Hsu,3 Ogo Egbuna,3 Jihua Wu,2 Clapton Dias,3 Bassam Abosaleem,3 Jitesh Rana,3 Maria Laura Monsalvo,3 Xue-Ning Li,1 Zhigang Yu4 1Department of Clinical Pharmacology ...
Liu C, Lu H, Yuan F, Chen WL, Xu HR, Li H, Hsu CP, Egbuna O, Wu J, Dias C, Abosaleem B, Rana J, Monsalvo ML, Li XN, Yu Z   +14 more
doaj  

UEG Week 2025 Poster Presentations

United European Gastroenterology Journal, Volume 13, Issue S8, Page S803-S1476, October 2025.
wiley   +1 more source

Retargeting the management of hypercholesterolemia – focus on evolocumab

Therapeutics and Clinical Risk Management, 2016
Alessandro Colletti,1 Giuseppe Derosa,2 Arrigo FG Cicero1 1Department of Medical and Surgical Sciences, University of Bologna, Bologna, 2Department of Internal Medicine and Therapeutics, University of Pavia and Policlinico San Matteo Foundation, Pavia ...
Colletti A, Derosa G, Cicero AFG
doaj  

PCSK9 as a Biomarker for Cardiovascular Risk [PDF]

Background: Proprotein convertase subtilisin/kexin 9 (PCSK9) is a protein that prevents low-density lipoprotein (LDL) clearance from plasma through degradation of low-density lipoprotein receptors (LDL-R).
McKinnon, Tyler J
core   +1 more source

Effect of evolocumab on the gut microbiota in patients with acute myocardial infarction. [PDF]

J Med Microbiol
Zou J, Peng Y, Cai H, Zhong Q, Zhu N, Gu W, Yang F, Shi T, Yang S, Chen L.   +9 more
europepmc   +1 more source